The TGA’s safety alert published on Monday said it had updated the product warnings for the class of high-profile drugs formally used to treat type 2 diabetes and obesity in Australia following investigations by international regulators. Read more from Kate Aubusson: https://lnkd.in/gmhBrAFi
